These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32628819)

  • 1. The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
    Paul B; Zhao Y; Loitsch G; Feinberg D; Mathews P; Barak I; Dupuis M; Li Z; Rein L; Wang E; Kang Y
    Cancer Med; 2020 Aug; 9(16):5869-5880. PubMed ID: 32628819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow fibrosis in newly diagnosed multiple myeloma and its correlation with clinicopathological factors.
    Hu X; Dai X; Guo X; Jiang X; Li Y; Zhao H; Lu J; Li X; Jin M
    Diagn Pathol; 2024 Jul; 19(1):99. PubMed ID: 39026319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis.
    Jamieson C; Hasserjian R; Gotlib J; Cortes J; Stone R; Talpaz M; Thiele J; Rodig S; Pozdnyakova O
    J Transl Med; 2015 Sep; 13():294. PubMed ID: 26357842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of bone marrow fibrosis in multiple myeloma.
    Subramanian R; Basu D; Dutta TK
    Pathology; 2007 Oct; 39(5):512-5. PubMed ID: 17886102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain.
    Hernández-Rivas JÁ; Arnao M; Arguiñano Pérez JM; Rubio A; García EG; de Miguel D; Cherepanov D; Romanus D; Verleger K; Johnson C; Corman SL; Grande M; Persona EP
    Future Oncol; 2021 Sep; 17(26):3465-3476. PubMed ID: 34342494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of bone marrow fibrosis in diffuse large B-cell lymphoma.
    Cetintepe T; Ozkan G; Kucukzeybek BP; Cetintepe L; Unal DK; Solmaz S; Aygun K; Acar AG; Bener S; Çallı AO; Payzın KB
    Int J Lab Hematol; 2024 Jun; 46(3):523-530. PubMed ID: 38361314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study.
    Liang D; Li X; Bai S; Wang Q; Zeng M; Feng D; Lu B; Li X; Sun Z; Li J; Zhou H; Zhang J; Chen X; Xia Z; Liang Y; Wang H
    Cancer Med; 2024 Oct; 13(20):e70270. PubMed ID: 39422477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
    Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
    Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
    Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
    Danziger SA; McConnell M; Gockley J; Young MH; Rosenthal A; Schmitz F; Reiss DJ; Farmer P; Alapat DV; Singh A; Ashby C; Bauer M; Ren Y; Smith K; Couto SS; van Rhee F; Davies F; Zangari M; Petty N; Orlowski RZ; Dhodapkar MV; Copeland WB; Fox B; Hoering A; Fitch A; Newhall K; Barlogie B; Trotter MWB; Hershberg RM; Walker BA; Dervan AP; Ratushny AV; Morgan GJ
    PLoS Med; 2020 Nov; 17(11):e1003323. PubMed ID: 33147277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
    Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
    Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Extended Treatment Interval on the Prognosis of Multiple Myeloma Patients: A Retrospective Study.
    Sun C; Ye JN; Mao JJ; Ma KW; Zhou X
    Oncol Res Treat; 2020; 43(11):592-604. PubMed ID: 33045715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
    Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
    Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor β- and interleukin 13-producing mast cells are associated with fibrosis in bone marrow.
    Nakayama S; Yokote T; Hiraoka N; Akioka T; Nishiwaki U; Miyoshi T; Iwaki K; Fumimoto A; Masuda Y; Hatooka J; Fujimoto M; Nishimura Y; Tsuji M
    Hum Pathol; 2017 Apr; 62():180-186. PubMed ID: 28159675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
    Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
    Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.
    Avivi I; Cohen YC; Suska A; Shragai T; Mikala G; Garderet L; Seny GM; Glickman S; Jayabalan DS; Niesvizky R; Gozzetti A; Wiśniewska-Piąty K; Waszczuk-Gajda A; Usnarska-Zubkiewicz L; Hus I; Guzicka R; Radocha J; Milunovic V; Davila J; Gentile M; Castillo JJ; Jurczyszyn A
    Am J Hematol; 2019 Oct; 94(10):1132-1140. PubMed ID: 31334859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
    López-Corral L; Caballero-Velázquez T; López-Godino O; Rosiñol L; Pérez-Vicente S; Fernandez-Avilés F; Krsnik I; Morillo D; Heras I; Morgades M; Rifon JJ; Sampol A; Iniesta F; Ocio EM; Martin J; Rovira M; Cabero M; Castilla-Llorente C; Ribera JM; Torres-Juan M; Moraleda JM; Martinez C; Vázquez A; Gutierrez G; Caballero D; San Miguel JF; Mateos MV; Pérez-Simón JA
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1703-1712. PubMed ID: 31054983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapies for multiple myeloma.
    Wallington-Beddoe CT; Pitson SM
    Aging (Albany NY); 2017 Aug; 9(8):1857-1858. PubMed ID: 28854147
    [No Abstract]   [Full Text] [Related]  

  • 20. Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.
    Romano A; Santoro M; Conticello C; Siragusa S; DI Raimondo F; Martinelli G; Cerchione C
    Panminerva Med; 2021 Mar; 63(1):13-20. PubMed ID: 32955184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.